| Product Number : |
CL2746 |
| Product Name : |
Lenacapavir(GS-6207) |
| CAS No. : |
2189684-44-2 |
| Synonyms : |
GS-6207 |
| Chemical Name : |
|
| Molecular Formula : |
C39H32ClF10N7O5S2 |
| Molecular Weight : |
968.28 |
| Molecular Structure : |
 |
| Appearance : |
White to light yellow powder |
| Specification : |
98+% |
| Application : |
|
| Registration : |
|
| Storage Condition : |
Lenacapavir (GS-6207) is a novel, first-in-class,long-acting and highly potent HIV-1 capsid inhibitor approved in EU on August 22, 2022 to treat HIV patients infected with multidrug-resistant virus and as a twice-yearly injectable for pre-exposure prophylaxis.
Statement:
->>Products covered by valid patents are not offered or supplied for commercial use.
->>Products currently covered by valid US Patents are offered for laboratory R&D use in accordance with 35 USC 271(e)+A13(1).
->>Any patent infringement and resulting liability is solely at buyer's risk.
->>Our products are only raw materials for drugs or industry, can't be used for human or animals directly.
